IN2012DN06581A - - Google Patents

Download PDF

Info

Publication number
IN2012DN06581A
IN2012DN06581A IN6581DEN2012A IN2012DN06581A IN 2012DN06581 A IN2012DN06581 A IN 2012DN06581A IN 6581DEN2012 A IN6581DEN2012 A IN 6581DEN2012A IN 2012DN06581 A IN2012DN06581 A IN 2012DN06581A
Authority
IN
India
Prior art keywords
compositions
active ingredients
carriers
eye
useful
Prior art date
Application number
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Günther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN06581A publication Critical patent/IN2012DN06581A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN6581DEN2012 2010-03-17 2011-03-16 IN2012DN06581A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10002800 2010-03-17
PCT/EP2011/053949 WO2011113855A2 (en) 2010-03-17 2011-03-16 Pharmaceutical composition for treatment of increased intraocular pressure

Publications (1)

Publication Number Publication Date
IN2012DN06581A true IN2012DN06581A (enExample) 2015-10-23

Family

ID=42223897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6581DEN2012 IN2012DN06581A (enExample) 2010-03-17 2011-03-16

Country Status (14)

Country Link
US (4) US10045996B2 (enExample)
EP (1) EP2547323B1 (enExample)
JP (1) JP5816636B2 (enExample)
KR (1) KR101656121B1 (enExample)
CN (1) CN102869345B (enExample)
AU (1) AU2011229235B2 (enExample)
BR (1) BR112012023421B1 (enExample)
CA (1) CA2788060C (enExample)
DK (1) DK2547323T3 (enExample)
ES (1) ES2564502T3 (enExample)
IN (1) IN2012DN06581A (enExample)
MX (1) MX2012010684A (enExample)
PL (1) PL2547323T3 (enExample)
WO (1) WO2011113855A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2013188283A1 (en) 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
US9770508B2 (en) 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
CN113694048B (zh) 2012-09-12 2023-03-24 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK2708228T3 (en) * 2012-09-12 2018-08-20 Novaliq Gmbh COMPOSITION FOR EYE RINSE
EP2783703A1 (en) * 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
AU2015227307A1 (en) 2014-03-03 2016-10-13 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
CN104606173A (zh) * 2014-12-26 2015-05-13 上海杰视医疗科技有限公司 一种含氟烷烃的用途
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
PL3356313T3 (pl) 2015-09-30 2020-11-16 Novaliq Gmbh 2-perfluoroheksylooktan do podawania okulistycznego
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3558308A1 (en) * 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
DK3399962T3 (da) 2016-12-23 2020-09-07 Novaliq Gmbh Oftalmisk sammensætning til behandling af tør øjensygdom
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
GB2580226B (en) * 2017-06-30 2022-08-31 Jenivision Inc Formulations for hair growth
IL273531B2 (en) * 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) * 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CA3097927A1 (en) * 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CA3144193A1 (en) * 2019-08-09 2021-02-18 Novaliq Gmbh Topical composition comprising a prostaglandin analogue
JP2022546980A (ja) 2019-09-06 2022-11-10 ノバリック ゲーエムベーハー ブドウ膜炎の治療のための眼科用組成物
JP2023527884A (ja) * 2020-06-01 2023-06-30 エーディーエス・セラピューティクス・エルエルシー 異常な血管新生を治療するための局所眼科用組成物および方法
WO2022169788A1 (en) 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
US6224887B1 (en) 1998-02-09 2001-05-01 Macrochem Corporation Antifungal nail lacquer and method using same
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
WO2000010531A1 (en) 1998-08-19 2000-03-02 Rtp Pharma Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CN1232244C (zh) 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
MXPA04001833A (es) 2001-09-04 2004-07-08 Trommsdorff Arzneimittel Emplasto para el tratamiento de disfunciones y desordenes del crecimiento de las unas.
EP1507513A1 (de) 2002-05-24 2005-02-23 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
AU2004266502B2 (en) 2002-10-25 2010-09-23 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
EP1684724A4 (en) 2003-11-19 2008-04-02 Barnes Jewish Hospital IMPROVED DRUG DELIVERY
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
EP1763336A1 (en) * 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
AU2006310113A1 (en) 2005-08-05 2007-05-10 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
US8328775B2 (en) 2006-12-07 2012-12-11 Sun Pharma Advanced Research Company Limited Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
ITMI20070890A1 (it) 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
EP2178502A2 (en) 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
AU2009308665B2 (en) 2008-10-31 2015-10-22 The University Of Mississippi Compositions containing delta-9-THC-amino acid esters and process of preparation
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
US9012503B2 (en) 2009-06-25 2015-04-21 Lion Corporation Ophthalmic composition
WO2011009436A2 (de) 2009-07-24 2011-01-27 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) * 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20140004197A1 (en) 2011-01-04 2014-01-02 Bastian Theisinger O/w-emulsions comprising semifluorinated alkanes
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2013110621A1 (en) 2012-01-23 2013-08-01 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
US9770508B2 (en) 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
CN113694048B (zh) 2012-09-12 2023-03-24 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
UY35195A (es) 2012-12-18 2014-07-31 Novartis Ag Composiciones y metodos para proteinas de accion prolongada
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
GB2544213B (en) 2014-08-13 2017-09-27 Univ Florida Preservative removal from eye drops
WO2016082644A1 (en) 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
WO2016108130A1 (en) 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
PL3356313T3 (pl) 2015-09-30 2020-11-16 Novaliq Gmbh 2-perfluoroheksylooktan do podawania okulistycznego
EP3463344A4 (en) 2016-06-01 2020-02-12 Harold Richard Hellstrom TREATMENT OF DRY EYE WITH PARASYMPATHIC AND ANTISYMPATHIC AGENTS
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US20190343793A1 (en) 2016-09-28 2019-11-14 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
EP3558308A1 (en) 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
DK3399962T3 (da) 2016-12-23 2020-09-07 Novaliq Gmbh Oftalmisk sammensætning til behandling af tør øjensygdom

Also Published As

Publication number Publication date
EP2547323A2 (en) 2013-01-23
CA2788060A1 (en) 2011-09-22
JP5816636B2 (ja) 2015-11-18
MX2012010684A (es) 2012-11-06
CN102869345A (zh) 2013-01-09
US10555953B2 (en) 2020-02-11
US10525062B2 (en) 2020-01-07
BR112012023421B1 (pt) 2021-09-14
DK2547323T3 (en) 2016-05-02
KR20130016280A (ko) 2013-02-14
US20190240234A1 (en) 2019-08-08
KR101656121B1 (ko) 2016-09-08
CA2788060C (en) 2017-07-11
US11324757B2 (en) 2022-05-10
US20200206241A1 (en) 2020-07-02
AU2011229235B2 (en) 2014-08-14
US10045996B2 (en) 2018-08-14
ES2564502T3 (es) 2016-03-23
HK1175398A1 (en) 2013-07-05
EP2547323B1 (en) 2016-01-27
AU2011229235A1 (en) 2012-09-13
WO2011113855A2 (en) 2011-09-22
CN102869345B (zh) 2015-02-11
PL2547323T3 (pl) 2016-07-29
JP2013522272A (ja) 2013-06-13
US20130046014A1 (en) 2013-02-21
WO2011113855A3 (en) 2011-11-17
US20180303849A1 (en) 2018-10-25
BR112012023421A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
IN2012DN06581A (enExample)
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EP3626253A3 (en) Stable formulations of linaclotide
MY183312A (en) Pharmaceutical formulation
EP4609866A3 (en) Oxysterols and methods of use thereof
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EP4218759A3 (en) Combination therapy
MY165087A (en) Neprilysin inhibitors
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
PH12016501462A1 (en) Neprilysin inhibitors
IN2014DN06869A (enExample)
MX2012012941A (es) Nuevas composiciones oftalmicas.
IN2014DN00090A (enExample)
NZ708821A (en) Lfa-1 inhibitor formulations
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
IN2014DN05972A (enExample)
EA201490573A1 (ru) Соединение бензотиазолона
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).